Australia - inglese - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - digoxin-specific antibody fragment f(ab) (ovine), quantity: 40 mg - injection, powder for - excipient ingredients: mannitol; sodium acetate - digoxin-specific antibody fragment f(ab) (ovine) digifab is indicated for the treatment of known (or strongly suspected) life-threatening digoxin toxicity associated with ventricular arrhythmias, progressive bradycardia, or second or third degree heart block not responsive to atropine, and where additional measures besides withdrawal of digoxin and correction of serum electrolyte abnormalities are considered necessary. consequences of multiple dosing with digifab have not been evaluated.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - cetrorelix, quantity: 0.25 mg - injection, powder for - excipient ingredients: mannitol - indications: prevention of premature luteinization and ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte pick up and assisted reproductive techniques. in clinical trials cetrotide was used with human menopausal gonadotrophin (hmg), however limited experience with recombinant fsh suggested similar efficacy.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - azathioprine, quantity: 50 mg - injection, powder for - excipient ingredients: sodium hydroxide - indications as at 11 february 2005: imuran is used as an immunosuppressant antimetabolite either alone, or more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. imuran, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. imuran, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering form the following: severe rheumatoid arthritis; systemic lupus erythematosus; dermatomyositis/polymyositis; autoimmune chronic active hepatitis; pemphigus vulgaris; polya

Australia - inglese - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: gelatin; mannitol; polyglactin - lucrin depot 7.5 mg injection and lucrin depot 3 month 22.5mg injection and lucrin depot 4 month 30mg injection are indicated in the palliative treatment of metastatic or locally extensive prostatic cancer (stage c and d).

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - parecoxib sodium, quantity: 42.36 mg (equivalent: parecoxib, qty 40 mg) - injection, powder for - excipient ingredients: sodium hydroxide; phosphoric acid; dibasic sodium phosphate - for a single peri-operative dose for the management of post-operative pain.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

abraxis bioscience australia pty ltd - paclitaxel, quantity: 100 mg - injection, powder for - excipient ingredients: albumin; sodium octanoate; sodium acetyltryptophanate - metastatic breast cancer abraxane is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. non-small cell lung cancer abraxane, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation. metastatic adenocarcinoma of the pancreas abraxane, in combination with gemcitabine, is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

abraxis bioscience australia pty ltd - paclitaxel, quantity: 250 mg - injection, powder for - excipient ingredients: albumin; sodium octanoate; sodium acetyltryptophanate - metastatic breast cancer abraxane is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. non-small cell lung cancer abraxane, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation. metastatic adenocarcinoma of the pancreas abraxane, in combination with gemcitabine, is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - ganciclovir sodium, quantity: 546 mg (equivalent: ganciclovir, qty 500 mg) - injection, powder for - excipient ingredients: - ganciclovir sxp (ganciclovir) administered as the iv infusion is indicated for the palliative treatment of confirmed sight-threatening cytomegalovirus (cmv) disease in aids and other severely immunocompromised individuals. it is indicated for the treatment of confirmed cmv pneumonitis in bone marrow transplant patients. it is also indicated for the prophylaxis of cmv infection and disease following bone marrow and solid organ transplantation in patients at risk of cmv disease.,note: ganciclovir sxp (ganciclovir) is not indicated for congenital or neonatal cmv disease; nor for the treatment of cmv infection in non-immunocompromised individuals.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - exenatide, quantity: 2 mg - injection, modified release - excipient ingredients: sucrose; polyglactin - exenatide is indicated for the treatment of type 2 diabetes mellitus to improve glycaemic control in combination with other glucose-lowering medicinal products when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control (see section 5.1 pharmacodynamic properties - clinical trials for available data on different combinations).

Australia - inglese - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - pasireotide embonate, quantity: 82.26 mg (equivalent: pasireotide, qty 60 mg) - injection, modified release - excipient ingredients: polyglactin glucose; polyglactin - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative or who are inadequately controlled on treatment with other somatostatin analogues.